|
[1] Huang L M, Jeang K T. HIV-1 at age 25: some thoughts for Taiwan and China. J Formos Med Assoc, 2008, 107:907-908.
[2] Louie M, Markowitz M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: A pathogenesis-based perspective. Antiviral Res, 2002, 55(1):15-25.
[3] Tilton J C, Doms R W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Research, 2010, 81:91-100.
[4] Moore J P, Doms R W. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA, 2003, 100 (19): 10598-10602.
[5] Callaha L N, Phelan M, Mallinson M, et al. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol, 1991, 65(3):1543-1550.
[6] Fischetti L, Barry S M, Hope T J, et al. HIV-1 infection of human penile explant tissue and protection by candidate microbicides. Aids, 2009, 23:319-328.
[7] Xiong S, Fan J, Kitazato K. The antiviral protein cyanovirin-N: the current state of its production and applications. Appl Microbiol Biotechnol, 2010, 86:805-812.
[8] Jacobson J M, Israel R J, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother, 2004, 48(2):423-429.
[9] Kadow J, Wang H G, Lin P F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: An emerging opportunity for drug development. Curr Opin Investig Drugs, 2006, 7(8):721-726.
[10] Jacobson, J M, Kuritzkes D R, Godofsky E, et al. Safety, Pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrobial Agents and Chemotherapy, 2009, 53(2):450-457.
[11] Vermeire K, Brouwers J, Herrewege Y V, et al. CADA, a Potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Current HIV Research, 2008, 6(3):246-256.
[12] Liu R, Paxton W A, Choe S, et al.Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 1996, 86:367-77.
[13] Huang C C, Lam S N, Acharya P, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfatedantibody with HIV-1 gp120 and CD4. Science, 2007, 317:1930-1934.
[14] Simmons G, Clapham P R, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 1997, 276(5310):276-279.
[15] Polo S, Nardese V, De Santis C, et al. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region:Dissociation from CCR5 activation. Eur J Immunol, 2000, 30(11):3190-3198.
[16] Jacobson J M, Lalezari J, Thompson M A, et al. Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, 2010, 54(10):4137-4142.
[17] Ji C, Zhang J, Dioszegi M, et al. CCR5 small molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by co-binding to the receptor. Mol. Pharmacol,2007, 72:18-28.
[18] Seto M, Aikawa K, Miyamoto N, et al. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. Journal of Medicinal Chemistry, 2006, 49(6):2037-2048.
[19] Cécile L T, Franoise G, Yongbiao G, et al. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro. American Society for Microbiology, 2005, 49(8):3483-3485.
[20] Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type1 activity. Antimicrobial Agents and Chemotherapy, 2005, 49(11):4721-4732.
[21] Tilton J C, Wilen C B, Didigu C A, et al. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol, 2010, 84(20):10863-10876.
[22] Strizki J M, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy, 2005, 49(12):4911-4919.
[23] Robert A O, Hou Y, Lei B, et al. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology, 2010,400:145-155.
[24] Seibert C, Ying W, Gavrilov S, et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology, 2006,349(1):41-54.
[25] Zou Y R, Kottmann A H, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature, 1998, 393(6685):595-599.
[26] Arakaki R, Tamamura H, Premanathan M, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol, 1999, 73(2):1719-1723.
[27] Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem Biophys Res Commun, 1998, 253(3):877-882.
[28] Fujii N, Oishi S, Hiramatsu K, et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. AngewChem Int Ed Engl, 2003, 42(28):3251-3253.
[29] Daelemans D, Schols D, Witvrouw M, et al. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol, 2000, 57(1):116-124.
[30] Liles W C, Rodger E, Broxmeyer H E, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion, 2005, 45: 295-300.
[31] Stone N D, Dunaway S B, Flexner C, et al. Multipledose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother, 2007, 51(7):2351-2358.
[32] Murakami T, Kumakura S, Yamazaki T, et al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother, 2009, 53:2940-2948.
[33] Iwasaki Y, Akari H, Murakami T, et al. Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci, 2009, 100: 778-781.
[34] Magombedze G, Garira W, Mwenje, E. Modelling the immunopathogen- esis of HIV-1 infection and the effect of multidrug therapy: the role of fusion inhibitors in HAART. Math Biosci Eng, 2008, 5(3):485-504.
[35] Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr, 2005,40(4):413-421.
[36] Dwyer J J, Wilson K L, Davison D K, et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA, 2007, 104: 12772-12777.
[37] Soonthornsata B, Tian Y S, Utachee P, et al. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41. Virology, 2010, 405: 157-164.
[38] Huang W, Groothuys S, Heredia A, et al. Enzymatic glycosylation of triazole-linked GlcNAc/Glc-Peptides:synthesis,stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues. ChemBioChem, 2009,10(7)1234-1242.
[39] Watabe T, Terakawa Y, Watanabe K, et al. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution. J Mol Biol, 2009, 392:657-665.
[40] FusoGen. Available at: http://www.fusogen.com en/indexen.asp.html.Date accessed: August 2, 2010].
[41] Deng Y, Zheng Q, Ketas T J, et al. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry,2007, 46:4360-4369.
[42] . Pang W, Wang R R, Yang L M, et al. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology, 2008, 377:80-87.
[43] He Y, Liu S, Jing W, et al. Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for sixhelix bundle stability and virus entry. J Biol Chem, 2007, 282:25631-25639.
[44] Huang L, Lai W, Ho P, et al. Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. AIDS Res Hum Retroviruses, 2007, 23(1):28-32.
[45] Ji C, Zhang J, Dioszegi M, et al. CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol Pharmacol, 2007, 72: 18-28.
[46] Pan C, Cai L, Lu H, et al. Combinations of the first and next generation HIV fusion inhibitors exhibit highly potent synergistic effect against enfuvirtide-sensitive and resistant HIV-1 strains. J Virol, 2009, 83:7862-7872.
[47] Ho D D. Therapy of HIV infections: problems and prospects. Bull N Y Acad Med, 1996, 73:37-45.
[48] Kopetzki E, Jekle A, Ji C, et al. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. J Virol, 2008, 5:56.
[49] Jekle A, Chow E, Kopetzki E, et al. CD4-BFFI: A novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Resaerch, 2009, 83:257-266.
|
